

Special Issue

Brain Injury: New Insights into Mechanisms and Future Promising Treatments

Message from the Guest Editors

Every year, more than 85 million people suffer from acquired brain injuries, with traumatic injury and stroke being their most common causes. Most of the therapeutic approaches in brain injury management used thus far in preclinical and clinical studies have been focused on attempts to reduce the sequelae of the injury and enhance the function of the remaining brain tissue. However, this approach does not address the need to regenerate or replace damaged or necrotic tissue. One of the promising approaches for the repair of traumatically injured brains involves using nanotechnology and tissue engineering approaches, techniques that focus on bridging the structural gaps and allowing the reconnection of the severed neuronal processes.

This Special Issue aims to cover the current research from preclinical and clinical studies, as well as reviews, and to identify the current knowledge and opportunities for future tailored research concerning the field of brain injury mechanisms and treatment, with an emphasis on regenerative and restoration techniques. Submissions that focus on the neuropathological molecular mechanisms involved in brain injury pathophysiology are also encouraged.

Guest Editors

Dr. Kristina Pilipović

Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Dr. Petra Dolenc

Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Deadline for manuscript submissions

closed (30 September 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/163907

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).